Two more deaths reported from Natrecor study

01/3/2006 | ABC News

Johnson & Johnson unit Scios reported two additional deaths occurred during a study of its heart failure drug Natrecor three years ago, but the company said the cases do not indicate increased risk from the drug. A total of seven patients died within 30 days of treatment with Natrecor. The company is preparing a report for the FDA due by April, and the authors of a report on the original study published in the October 2005 issue of the Journal of Emergency Medicine will update their report.

View Full Article in:

ABC News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX